Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
NCT ID: NCT00420563
Last Updated: 2012-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
88 participants
INTERVENTIONAL
2006-09-30
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CYCLOPHOSPHAMIDE
CYCLOPHOSPHAMIDE
50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
MEGESTROL
MEGESTROL
320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CYCLOPHOSPHAMIDE
50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
MEGESTROL
320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PS-WHO \< or = 1
* Histologically proven cancer
* No other therapeutic proposal
* Treatment can be orally taken
* Radiologic proof of evolutive character of the disease
* Effective contraception
Exclusion Criteria
* Breast cancer
* Thrombosis or pulmonary embolism
* Dysphagia, malabsorption
* Polynuclear neutrophil leukocytes \< 1000/mm3
* Treatment with Tegretol
* Active and uncontrolled infection
* Evolutive psychiatric disease
* Pregnant or lactating woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Oscar Lambret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PENEL Nicolas, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Oscar Lambret
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Oscar Lambret
Lille, , France
Hopital Saint Vincent
Lille, , France
Centre Hospitalier Regional - Dermatology
Lille, , France
Centre Hospitalier Regional - Oncology
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PAL-ANGI 0601
Identifier Type: -
Identifier Source: org_study_id